I think to treat a negative pressure tissue site and systems, devices and methods

专利摘要:
This is a dressing to treat a negative pressure tissue site that may include a first layer that has a first side, a second side and fenestrations that have a raised edge extending from the first side. The raised edge is configured to expand in response to a pressure gradient across the first layer. The dressing also includes a second layer adjacent to the first side. The second layer includes a transmitter. The dressing also includes a cover attached to the second layer opposite the first layer. The cover includes a polymer cloth.
公开号:BR112019025031A2
申请号:R112019025031-0
申请日:2018-06-05
公开日:2020-08-18
发明作者:Christopher Brian Locke；Timothy Mark Robinson
申请人:Kci Licensing, Inc；
IPC主号:

专利说明:

[0001] [0001] This application claims the benefit, provided for in title 35 of USC S 119 (e), of the filing of provisional patent application No. US 62 / 565,754, entitled “COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE-PRESSURE TREATMENT” , filed on September 29, 2017; the provisional patent application in U.S. 62 / 516,540, entitled “TISSUE CONTACT INTERFACE”, filed on June 7, 2017; U.S. Provisional Patent Application 62 / 516,550, entitled “COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE-PRESSURE TREATMENT”, filed June 7, 2017; and provisional patent application in U.S. 62 / 516,566, entitled “COMPOSITE
[0002] [0002] The invention presented in the appended claims relates, in general, to tissue treatment systems and, more particularly, but without limitation, to tissue treatment patches and methods for using tissue treatment patches. BACKGROUND
[0003] [0003] Studies and clinical practices have shown that reducing pressure near a tissue site can increase and accelerate the growth of new tissue at the tissue site. There are numerous applications for this phenomenon, but they have proved to be particularly advantageous for treating injuries. Regardless of the aetiology of an injury, be it trauma, surgery or another reason, proper care of the injury is important to the outcome. The treatment of wounds or other tissues with reduced pressure may be commonly called “negative pressure therapy”, but it is also known by other names, including “negative pressure injury therapy”, “reduced pressure therapy”, “vacuum therapy ”,“ Vacuum-assisted closure ”and“ topical negative pressure ”, for example. Negative pressure therapy can provide several benefits, including migration of epithelial and subcutaneous tissues, improved blood flow and microdeformation of the tissue at a wound site. Together, these benefits can increase the development of granulation tissue and reduce the healing time.
[0004] [0004] There is also widespread acceptance that cleaning a tissue site can be highly beneficial for new tissue growth. For example, a wound can be washed with a stream of liquid solution, or a cavity can be washed with the use of a liquid solution for therapeutic purposes. These practices are commonly called “irrigation” and “washing”, respectively. “Instillation” is another practice that generally refers to a process of slowly introducing the fluid into a tissue site and maintaining the fluid for a prescribed period of time before removing the fluid. For example, instilling topical treatment solutions onto a wound bed can be combined with negative pressure therapy to further promote wound healing by loosening soluble contaminants into a wound bed and removing infectious material.
[0005] [0005] While the clinical benefits of negative pressure therapy and / or instillation therapy are widely known, improvements in therapy systems, components and processes can benefit healthcare professionals and patients. BRIEF SUMMARY
[0006] [0006] New and useful systems, apparatus and methods for treating tissue in a negative pressure therapy environment are presented in the appended claims. Illustrative modalities are also provided to enable an individual skilled in the art to produce and use the claimed material.
[0007] [0007] For example, in some embodiments, a dressing to treat fabric may be a composite of dressing layers, including a release film, a perforated polymer film, an open cell foam and an adhesive cloth. Some dressings may also include a bonded silicone that has perforations. The perforation pattern of the polymeric film can be aligned with the perforation pattern of at least one central area of the silicone. In some embodiments, the perforations may be slits or notches. In some embodiments, perforations may include fenestrations that have a raised edge extending from the first side of the polymeric film. The polymeric film can be hydrophobic and can have a contact angle with water greater than 90 degrees. The polymeric film may comprise or consist of a polyethylene film or an ethyl methyl acrylate film. The polymeric film can have an area density of less than 30 grams per square meter. The open cell foam can be cross-linked foam in some examples, and can be relatively thin and hydrophobic to reduce the fluid's holding capacity of the dressing. The foam can also be thin to reduce the profile of the dressing and increase flexibility, which can enable it to conform to wound beds and other tissue sites under negative pressure. In some embodiments, the polymeric film is welded to the foam using heat, radiofrequency welding or a method to generate heat, such as ultrasonic.
[0008] [0008] In some embodiments, a dressing to treat a tissue site with negative pressure may include a first layer that has a first side, a second side and fenestrations that have a raised edge extending from the first side, with the raised edge is configured to expand in response to a pressure gradient through the first layer; a second layer adjacent to the first side, the second layer comprising a transmitter; and a cover attached to the second layer opposite the first layer, the cover comprising a polymer cloth.
[0009] [0009] In some embodiments, a dressing to treat a tissue site with negative pressure may include a first layer comprising a film that has perforations and fenestrations through the film that are configured to expand in response to a pressure gradient across the film ; a second layer adjacent to the first layer, the second layer comprising a transmitter; and a cover adjacent to the second layer opposite the first layer.
[0010] [0010] In some embodiments, a dressing to treat a tissue site with negative pressure may include a fluid control layer that comprises fluid constraints that are elastomeric and configured to be responsive to a pressure gradient across the pressure control layer. fluid; a transmitting layer adjacent to the fluid control layer; a cover adjacent to the transmitting layer opposite the fluid control layer; and a sealing layer adjacent to the fluid control layer opposite the transmitting layer. The sealing layer may include openings aligned with fluid restrictions. The fluid control layer and the sealing layer can each have a water contact angle of at least 70 degrees. The fluid control layer and the sealing layer can each be less than 100 microns thick. The fluid control layer and the sealing layer can have a hardness in the range of 20 Shore A to 90 Shore A.
[0011] [0011] Objectives, advantages and a preferential way to produce and use the claimed material can be better understood by referring to the attached drawings together with the detailed description below of the illustrative modalities. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] [0012] Figure 1 is a functional block diagram of an exemplary modality of a therapy system that can provide tissue treatment according to this specification;
[0013] [0013] Figure 2 is an assembly view of an example of a dressing that illustrates additional details that can be associated with some exemplary modalities of the therapy system of Figure 1;
[0014] [0014] Figure 3 is a schematic view of an exemplary configuration of fluid restrictions in a layer that can be associated with some modalities of the dressing of Figure 2;
[0015] [0015] Figure 4 is a detailed view of exemplary fluid restrictions in a closed and an open state illustrating additional details that can be associated with some embodiments of the dressing in Figure 2;
[0016] [0016] Figure 5 is a detailed view of other exemplary fluid restrictions that can be associated with some embodiments of the dressing of Figure 2;
[0017] [0017] Figure 6 is a detailed view of other exemplary fluid restrictions that can be associated with some embodiments of the dressing in Figure 2;
[0018] [0018] Figure 7 is an assembly view of another example of a dressing that illustrates additional details that can be associated with some exemplary embodiment of the therapy system of Figure 1;
[0019] [0019] Figure 8 is a schematic view of an exemplary configuration of openings in a layer that can be associated with some modalities of the dressing of Figure 7;
[0020] [0020] Figure 9 is a schematic view of the exemplary layer of Figure 8 superimposed on the exemplary layer of Figure 3;
[0021] [0021] Figure 10 is a schematic view of another exemplary configuration of fluid restrictions that can be associated with some modalities of a dressing in the therapy system of Figure 1;
[0022] [0022] Figure 11 and Figure 12 illustrate other exemplary configurations of fluid restrictions that can be associated with some embodiments of the dressing of Figure 2 or Figure 4;
[0023] [0023] Figure 13 is a view of the assembly that illustrates an example of a tissue interface that can be associated with some modalities of the therapy system of Figure 17
[0024] [0024] Figure 14 is a schematic sectional view of an exemplary transmitter that can be associated with some modalities of the dressing of Figure 1;
[0025] [0025] Figure 15 is a perspective view of an exemplary transmitter that can be associated with some modalities of the dressing of Figure 1; and
[0026] [0026] Figure 16 illustrates another example transmitter that can be associated with some modalities of the dressing of Figure 1. DESCRIPTION OF EXEMPLIFICATIVE MODALITIES
[0027] [0027] The following description of the exemplary modalities provides information that enables an individual skilled in the art to produce and use the material presented in the attached claims and may omit certain details already well known in the art. The following detailed description should therefore be considered illustrative and not limiting.
[0028] [0028] The exemplary modalities can also be described in this document with reference to the spatial relationships between various elements or the spatial orientation of various elements represented in the attached drawings. In general, such relationships or guidance assume a consistent or relative frame of reference for a patient in a position to receive treatment. However, as it should be recognized by those skilled in the art, this frame of reference is merely a descriptive file, rather than a strict prescription.
[0029] [0029] Figure 1 is a simplified functional block diagram of an exemplary modality of a therapy system 100 that can deliver negative pressure therapy with instillation of topical treatment solutions to a tissue site according to this specification.
[0030] [0030] The term "tissue site", in this context, refers broadly to an injury, defect or other treatment target located in or within the tissue, including, but not limited to, a superficial wound, bone tissue, tissue adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons or ligaments. The term "tissue site" can also refer to areas of any tissue that are not necessarily injured or defective, but are instead areas in which it may be desirable to add or promote additional tissue growth. For example, negative pressure can be applied to a tissue site to grow additional tissue that can be harvested and transplanted. A superficial wound, as used herein, is a wound on the surface of a body that is exposed to the outer surface of the body, such as injury or damage to the epidermis, dermis and / or subcutaneous layers. Superficial wounds can include ulcers or closed incisions, for example. A superficial wound, as used herein, does not include injuries to an intra-abdominal cavity. An injury can include chronic, acute, traumatic, subacute and dehiscent wounds, partial thickness burns, ulcers (such as diabetic, pressure or venous insufficiency), flaps and grafts, for example.
[0031] [0031] Therapy system 100 may include a negative pressure source or supply, such as a negative pressure source 102, a dressing 104, a fluid container, such as a container 106, and a regulator or controller, such as a controller 108, for example. In addition, therapy system 100 may include sensors for measuring operational parameters and providing feedback signals to controller 108 indicative of operating parameters. As shown in Figure 1, for example, therapy system 100 may include a first sensor 110 and a second sensor 112 coupled to controller 108. As shown in the example in Figure 1, dressing 104 may comprise or consist essentially of one or more dressing layers, such as a fabric interface 114, a cover 116 (or cloth), or both in some embodiments.
[0032] [0032] Therapy system 100 may also include a source of instillation solution, such as saline, for example. For example, a source of solution 118 can be fluidly coupled to dressing 104, as illustrated in the exemplary embodiment of Figure 11. Solution source 118 can be fluidly coupled to a positive pressure source, such as positive pressure source 120, to a negative pressure source, such as negative pressure source 102, or both in some embodiments. A regulator, such as an instillation regulator 122, can also be fluidly coupled to the solution source 118 and dressing 104 to ensure proper dosing of instillation solution to a tissue site. For example, instillation regulator 122 may comprise a piston that can be pneumatically actuated by the negative pressure source 102 to extract instillation solution from the solution source during a negative pressure interval and instill the solution into a dressing during a ventilation interval. . Additionally or alternatively, controller 108 can be coupled to the negative pressure source 102, the positive pressure source 120 or both, to control the dosage of instillation solution to a tissue site. In some embodiments, the instillation regulator 122 can also be fluidly coupled to the negative pressure source 102 via dressing 104, as shown in the example in Figure 1.
[0033] [0033] Some components of the therapy system 100 can be housed or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices or user interfaces that facilitate further therapy. For example, in some embodiments, the negative pressure source 102 can be combined with the solution source 118, the controller 108 and other components in a therapy unit.
[0034] [0034] In general, the components of the therapy system 100 can be coupled directly or indirectly. For example, the negative pressure source 102 can be directly coupled to container 106 and can be indirectly coupled to dressing 104 via container 106. The coupling can include fluid, mechanical, thermal, electrical or chemical coupling (such as a chemical bond) , or some combination of couplings in some contexts. For example, the negative pressure source 102 can be electrically coupled to controller 108. The negative pressure source can be fluidly coupled to one or more delivery components, which provide a fluid path to a tissue site. In some embodiments, the components can also be coupled due to physical proximity, being an integral part of a single structure or formed from the same piece of material. For example, the fabric interface 114 and the cover 116 can be separate layers arranged adjacent to each other and can be joined in some embodiments.
[0035] [0035] A distribution component is preferably removable and can be disposable, reusable or recyclable. Dressing 104 and container 106 are illustrations of the delivery components. A fluid conductor is another illustrative example of a distribution component. A "fluid conductor" in this context broadly includes a tube, pipe, hose, conduit or other structure with one or more lumens or open paths adapted to transport a fluid between two ends. Typically, a tube is an elongated cylindrical structure with some flexibility, but the geometry and stiffness can vary. In addition, some fluid conductors can be molded or otherwise integrally combined with other components. Distribution components can also include or comprise interfaces or fluid ports to facilitate the coupling and uncoupling of other components, including sensors and data communication devices. In some embodiments, for example, a dressing interface can facilitate the coupling of a fluid conductor to the dressing
[0036] [0036] A negative pressure supply, such as negative pressure source 102, can be an air reservoir at negative pressure or it can be a manual or electrically powered device, such as a vacuum pump, a suction pump, a suction port to the wall available in many health care facilities or a micro pump, for example. "Negative pressure" generally refers to a pressure less than a local ambient pressure, such as ambient pressure in a local environment outside a sealed therapeutic environment. In many cases, the local ambient pressure can also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with the tissue at the tissue site. Unless otherwise stated, the pressure values mentioned in this document are effective pressures. negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure, although the amount and nature of negative pressure applied to a tissue site can vary from according to therapeutic requirements, the pressure is generally low vacuum, also commonly called raw vacuum, between -5 mm Hg (-667 Pa) and -500 mm Hg (-6 6.7 kPa) Common therapeutic ranges are between -50 mm Hg (-6.7 kPa) and -—- 300 mm Hg (-39.9 kPa).
[0037] [0037] Container 106 is representative of a container, ampoule, pouch or other storage component that can be used to manage exudate and other fluid extracted from a tissue site. In many environments, a rigid container may be preferred or necessary for the collection, storage and disposal of fluid. In other environments, the fluid can be properly disposed of without storing the rigid container, and a reusable container could reduce the waste and costs associated with negative pressure therapy. Additionally or alternatively, an absorbent can be integrated with dressing 104 to manage the fluid extracted from a tissue site.
[0038] [0038] A controller, such as controller 108, can be a microprocessor or computer programmed to operate one or more components of the therapy system 100, such as the negative pressure source 102. In some embodiments, for example, controller 108 it can be a microcontroller that generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. Operational parameters may include the power applied to the negative pressure source 102, the pressure generated by the negative pressure source 102 or the pressure distributed to the tissue interface 114, for example. Controller 108 is preferably also configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operational parameters based on the input signals.
[0039] [0039] Sensors, such as the first sensor 110 and the second sensor 112, are generally known in the art as any operable device for detecting or measuring a phenomenon or physical property and generally provide a signal indicative of the phenomenon or property that is detected or measured. For example, the first sensor 110 and the second sensor 112 can be configured to measure one or more operating parameters of the therapy system 100. In some embodiments, the first sensor 110 can be a transducer configured to measure pressure on a pneumatic path and convert the measurement into a signal indicating the measured pressure. In some embodiments, for example, the first sensor 110 may be a piezoresistive stretch meter. The second sensor 112 can optionally measure operating parameters of the negative pressure source 102, such as voltage or current, in some embodiments. Preferably, the signals from the first sensor 110 and the second sensor 112 are suitable as an input signal to controller 108, but some signal conditioning may be suitable in some embodiments. For example, the signal may need to be filtered or amplified before it can be processed by the controller
[0040] [0040] The fabric interface 114 can generally be adapted to contact a fabric site. The fabric interface 114 can be, partially or totally, in contact with the fabric site. If the tissue site is a wound, for example, the tissue interface 114 can partially or completely fill the wound, or it can be placed over the wound. The fabric interface 114 can take any shape and have more than one layer in some embodiments. The fabric interface 114 can also have many sizes, shapes or thicknesses, depending on a variety of factors, such as the treatment top to be implemented or the nature and size of a fabric site. For example, the size and shape of the fabric interface 114 can be adapted to the contours of deep and irregularly shaped fabric sites.
[0041] [0041] In some embodiments, coverage 116 can provide a bacterial barrier and protection against physical trauma. The cover 116 can also be constructed from a material that can reduce evaporative losses and provide a fluid seal between the two components or two environments, such as between a therapeutic environment and a local external environment. The cover 116 can be, for example, a film or elastomeric membrane that can provide an adequate seal to maintain a negative pressure at a tissue site for a given source of negative pressure. Cover 116 may have a high vapor transmission and humidification rate (MVTR) in some applications. For example, can the MVTR be at least 300 g / m for twenty-four hours in some modalities. In some exemplary embodiments, cover 116 may be a polymer cloth, such as a polyurethane film, permeable to water vapor but impermeable to liquids. Such cloths typically have a thickness in the range of 25 to 50 microns. For permeable materials, the permeability should generally be low enough that a desired negative pressure can be maintained. The cover 116 may comprise, for example, one or more of the following materials: hydrophilic polyurethane; cellulosic; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; hydrophilic silicone elastomers; an INSPIRE 2301 material from Coveris Advanced Coatings of Wrexham, United Kingdom, which has, for example, an MVTR (inverted glass technique) of 14,400 g / m2 / 24 hours and a thickness of about microns; a thin uncoated polymer cloth; natural rubbers; polyisoprene; styrene-butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene-propylene rubber; ethylene-propylene-diene monomer; chlorosulfonated polyethylene; polysulfide rubber; polyurethane (PU); EVA film; copolyester; silicones; a silicone cloth; a 3M Tegadermo cloth; a polyurethane (PU) cloth, such as that available from Avery Dennison Corporation of Glendale, California; polyamide polyether block copolymer (PEBAX), for example, from Arkema, France; INSPIRE 2327; or other suitable material.
[0042] [0042] A fixing device can be used to fix the cover 116 to a fixation surface, such as undamaged skin, a gasket or another cover. The fixing device can take any shape. For example, a fixation device can be a medically acceptable pressure sensitive adhesive configured to attach the cover 116 to the epidermis around a tissue site, such as a superficial wound. In some embodiments, for example, part or all of the coverage 116 may be coated with an adhesive, such as an acrylic adhesive that can have a coating weight between 25 and 65 grams per square meter (g / m2). Thicker adhesives or combinations of adhesives can be applied in some ways to improve sealing and reduce leakage. Other exemplary embodiments of a fixture may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel or organogel.
[0043] [0043] Solution source 118 may also be representative of a container, ampoule, purse, bag or other storage component that can provide a solution for instillation therapy. Solution compositions may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include solutions based on hypochlorite, silver nitrate (0.5%), sulfur-based solutions, biguanides, solutions cationic and isotonic solutions.
[0044] [0044] Fluid mechanics for using a negative pressure source to reduce pressure in another component or location, such as in a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative pressure therapy and instillation are generally well known to those skilled in the art, and the process for reducing pressure can be described illustratively in this document as "delivery", "distribution" or “generation” of negative pressure, for example.
[0045] [0045] In general, exudate and other fluid flow towards the lowest pressure along a fluid path. Thus, the term "downstream" typically implies something in a fluid path relatively closer to a source of negative pressure or more distant from a source of positive pressure. In contrast, the term "upstream" implies something relatively farther from a source of negative pressure or closer to a source of positive pressure. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference. This guidance is generally assumed for purposes of describing various features and components in this document. However, the fluid path can also be reversed in some applications (such as replacing a source of positive pressure with a source of negative pressure), and this descriptive convention should not be interpreted as a limiting convention.
[0046] [0046] Figure 2 is an assembly view of an example of the dressing 104 of Figure 1 which illustrates additional details that can be associated with some embodiments in which the fabric interface 114 comprises more than one layer. In the example of Figure 2, the fabric interface 114 comprises a first layer 205 and a second layer 210. In some embodiments, the first layer 205 has a first side and a second side. The second layer 210 can be adjacent to the first side of the first layer 205. For example, the first layer 205 and the second layer 210 can be stacked so that the first layer 205 is in contact with the second layer
[0047] [0047] The first layer 205 may comprise or consist essentially of a means to control or manage the flow of fluid. In some embodiments, the first layer 205 may comprise or consist essentially of an elastomeric material that is impermeable to liquids. For example, the first layer 205 may comprise or consist essentially of a polymeric film. The first layer 205 may also have a smooth or matte surface texture in some embodiments. A satin or glossy finish better than or equal to a B3 grade according to SPI (Plastic Industry Society) standards can be particularly advantageous for some applications. In some embodiments, variations in the height of the surface may be limited. For example, the surface of the first layer 205 may have a substantially flat surface, with height variations limited to 0.2 millimeters over one centimeter.
[0048] [0048] In some embodiments, the first layer 205 may be hydrophobic and may be more hydrophobic than the second layer 210. The hydrophobicity of the first layer 205 may vary, but may have an angle of contact with water of at least 90 degrees in some modalities. In some embodiments, the first layer 205 may have a maximum contact angle of 150 degrees with water. For example, in some embodiments, the contact angle of the first layer 205 may be in a range of at least 70 degrees to about 120 degrees or in a range of at least 120 degrees to 150 degrees. The angles of contact with water can be measured using any standard device. Although manual goniometers can be used to visually approximate contact angles, contact angle measurement instruments can often include an integrated system that involves a level stage, a liquid dropper, such as a syringe, camera and software designed to calculate contact angles with more accuracy and precision, among other things. Non-limiting examples of such integrated systems may include the systems - FTÃ125, FTÃZOO, FTÃZO0OO and FTÃ4000, all commercially available from First Ten Angstroms, Inc., of Portsmouth, VA, and the DTA25, DTA30 and DTAI0O0 systems, all commercially available from to Kruss GmbH from Hamburg, Germany. Unless otherwise specified, the angles of contact with water in this document are measured using deionized and distilled water on a level sample surface for a sessile drop added from a maximum height of 5 cm in the air at 20 to 25 ºC and 20 to 50% relative humidity. The contact angles reported in this document represent averages of 5 to 9 measured values, discarding the values both higher and lower measured. The hydrophobicity of the first layer 205 can be further enhanced with a hydrophobic coating of other materials, such as silicones and fluorocarbons, whether coated with a liquid or coated with plasma.
[0049] [0049] The area density of the first layer 205 may vary according to a prescribed therapy or application. In some embodiments, an area density of less than 40 grams per square meter may be suitable, and an area density of about 20 to 30 grams per square meter may be particularly advantageous for some applications.
[0050] [0050] In some embodiments, for example, the first layer 205 may comprise or consist essentially of a hydrophobic polymer, such as a polyethylene film or ethyl methyl acrylate (EMA). The simple and inert structure of polyethylene can provide a surface that interacts little, if at all, with biological tissues and fluids, providing a surface that can encourage free flow of liquids and low adhesion, which can be particularly advantageous for many applications. Other suitable polymeric films include polyurethanes, acrylics, polyolefin (such as cyclic olefin copolymers) polyacetates, polyamides, polyesters, copolyesters, PEBAX block copolymers, thermoplastic elastomers, thermoplastic vulcanizers, polyethers, polyvinylphenols, polyethylene, polypropylene, polyethylene, polypropylene, polypropylene, polypropylene, polyethylene, polypropylene, polypropylene, polypropylene, polyethylene, polypropylene. silicones, fluoropolymers and acetates. A thickness between 20 microns and 100 microns can be suitable for many applications. Films can be transparent, colored or printed. Films can have a flexibility of 20 Shore A to 90 Shore A.
[0051] [0051] The first layer 205 can also be suitable for welding to other layers, including the second layer 210. For example, the first layer 205 can be adapted for welding to polyurethane foams using heat, radiofrequency (RF) welding ) or other methods to generate heat, such as ultrasonic welding. RF welding can be particularly suitable for more polar materials, such as polyurethane, polyamides, polyesters and acrylates. Polar sacrificial interfaces can be used to facilitate RF welding of less polar film materials, such as polyethylene. More polar films suitable for lamination to a polyethylene film include polyamide, copolyesters, ionomers and acrylics. To aid in the connection between a polyethylene and polar film, display layers can be used, such as ethylene vinyl acetate or modified polyurethanes. An ethyl methyl acrylate (EMA) film may also have suitable hydrophobic and welding properties for some configurations.
[0052] [0052] In some embodiments, the first layer 205 may include a polymeric film of polylactic acid, carboxymethyl cellulose or polycaprolactone. In other embodiments, the first layer 205 may include a film of xanthan gum mixed with at least one of collagen, oxidized regenerated cellulose and alginate. In some embodiments, the first layer 205 includes a film of xanthan gum and citric acid mixed with at least one of collagen, regenerated oxidized cellulose and alginate. The first layer 205 may include a film copolymerized with dialkylcarbamoyl chloride in some embodiments.
[0053] [0053] In some embodiments, the first layer 205 may be a film coated with petroleum jelly. Vaseline gel can have a viscosity of at least 10,000 millipascals seconds. In some embodiments, the petroleum jelly has antimicrobial compounds.
[0054] [0054] In some embodiments, instead of silicone and polyethylene films, the first 205 layer may include a long-lived bioresorbable polymeric film formed from polylactic acid, carboxymethylcellulose, polycaprolactone or other polymers that are capable of being crosslinked, so that the function is retained for more than about 7 days and resorption occurs in more than 12 days. In other embodiments, the first layer may include highly cross-linked biopolymers, such as collagen or alginate, which are mixed with xanthan gum in a 20% ratio between the gum and the biological product, and which is treated with plasma to achieve hydrophobicity in desired track. The film can also include citric acid to help reduce biofilm and limit concerns about bacterial build-up. In some modalities, the film is formed from polyethylene, polyurethane, EMA or biopolymers that incorporate a texture, such as the “Sharklet” that helps with the reduction of biofilm formation in the dressing. In other modalities, the film is copolymerized with dialkylcarbamoyl chloride, which is highly hydrophobic, and can help prevent biofilm and bacterial fixation.
[0055] [0055] As illustrated in the example of Figure 2, the first layer 205 can have one or more fluid restrictions 220 which can be distributed evenly and randomly through the first layer 205 and can restrict the transfer on or through the first layer.
[0056] [0056] For example, some modalities of fluid restrictions 220 may comprise or consist essentially of one or more fenestrations, perforations or combinations of fenestrations and perforations in the first layer
[0057] [0057] The second layer 210 generally comprises or consists essentially of a transmitter or a transmitting layer that provides a means for collecting or distributing fluid through the tissue interface 114 under pressure. For example, second layer 210 can be adapted to receive negative pressure from a source and distribute negative pressure through multiple openings through tissue interface 114, which can have the effect of collecting fluid from a tissue site and dragging the fluid towards the source. In some embodiments, the fluid path can be reversed or a secondary fluid path can be provided to facilitate fluid delivery, such as from an instillation solution source, through the tissue interface 114.
[0058] [0058] In some illustrative modalities, the paths of the second layer 210 can be interconnected to improve the distribution or collection of fluids. In some illustrative embodiments, the second layer 210 may comprise or consist essentially of a porous material that has interconnected fluid paths. For example, open cell foam, porous tissue collections and other porous material, such as gauze or felted foam, generally include pores, edges and / or walls adapted to form interconnected fluid channels. Other suitable materials may include a 3D textile (Baltex, Muller, Heathcoates), non-woven fabrics (Libeltex, Freudenberg), a 3D polymeric structure (molded polymers, embossed and formed films and melt-linked films [Supracore]) and mesh, for example . Liquids, gels and other foams can also include or be cured to include openings and fluid paths. In some embodiments, the second layer 210 may, additionally or alternatively, comprise projections that form interconnected fluid paths. For example, second layer 210 can be shaped to provide surface projections that define interconnected fluid paths. Any or all of the surfaces of the second layer 210 may have an irregular, coarse or jagged profile.
[0059] [0059] In some embodiments, the second layer 210 may comprise or consist essentially of cross-linked foam that has pore sizes and free volume that may vary according to the needs of a prescribed therapy. For example, cross-linked foam that has a free volume of at least 90% may be suitable for many therapy applications, and foam that has an average pore size in the range of 400 to 600 microns may be particularly suitable for some types of therapy. The tensile strength of the second layer 210 may also vary according to the needs of a prescribed therapy. For example, the tensile strength of the foam can be increased to instill topical treatment solutions. The 25% compression load deflection of the second layer 210 can be at least 0.025 kilograms per square centimeter (0.35 pounds per square inch), and the 65% compression load deflection can be at least 0.030 kilograms per square centimeter (0.43 pounds per square inch). In some embodiments, the tensile strength of the second layer 210 can be at least 0.7 kilograms per square centimeter (10 pounds per square inch). The second layer 210 can have a tensile strength of at least 0.45 kilogram per centimeter (2.5 pounds per inch). In some embodiments, the second layer 210 may be foam comprised of polyols, such as polyester or polyether, isocyanate, such as toluene diisocyanate, and polymerization modifiers, such as amines and tin compounds. In a non-limiting example, the second layer 210 may be a cross-linked polyurethane foam, such as that used in the GRANUFOAM dressing "" or in the V.A.C. VERAFLO ”" ", both available from KCI in San Antonio, Texas.
[0060] [0060] In some embodiments, the second layer 210 may be hydrophobic to minimize retention or storage of liquid in dressing 104. In other embodiments, the second layer 210 may be hydrophilic. In an example where the second layer 210 can be hydrophilic, the second layer 210 can also drain fluid from a tissue site, while continuing to distribute negative pressure to the tissue site. The drainage properties of the second layer 210 can drag the fluid in the opposite direction to a tissue site by capillary flow or other drainage mechanisms, for example. An example of a second hydrophilic layer 210 is an open cell foam of polyvinyl alcohol, such as the V.A.C. WHITEFOAM "available from KCI of San Antonio, Texas. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
[0061] [0061] In some embodiments, the second layer 210 may, additionally or alternatively, comprise or consist essentially of a polymeric mesh. The polymeric mesh can have an open area of at least 70%. In some embodiments, multiple layers of polymeric mesh may be included, so that a tortuous path is formed. Additionally or alternatively, the second layer 210 may comprise or consist essentially of a flocked layer, such as a film or other suitable fiber flocked substrate. A length of about 0.5 mm to about 6.0 mm may be suitable for some fiber modalities. In some embodiments, the second layer 210 may, additionally or alternatively, comprise or consist essentially of a perforated cellulose mat or a construction of perforated mat layers. Perforations can be continuous or discontinuous through the structure and, when more than one layer is included, the layers can incorporate films to control the flow direction. For example, cellulose can be treated to produce the hydrophobic material, and the fabric interface can be perforated after adhering to a mat. Additionally or alternatively, the second layer 210 may comprise or consist essentially of a layered structure of sheets of hydrofiber material, which can be sewn together to form a blanket. The seam can assist pressure and fluid communication. The stitched structure can be intercalated or replaced by a foamed version of this material, formed by means such as lyophilization, addition of foaming agents or by injection of gas under high pressure during manufacture.
[0062] [0062] In other embodiments, the second layer 210 may include layers of bonded non-woven materials that can be treated with plasma to create a desired level of hydrophobicity. In some embodiments, the second layer 210 may include one or more layers of closed-cell foam, which can be perforated to enable fluid and pressure transmission. The one or more layers may include a foam with aligned and misaligned vertical and horizontal perforations, so that transmission occurs. In some embodiments, the transmitting layer is formed from a flocked body. For example, a film can be coated with flocked fibers that have a length of about 0.5 mm to about 6.0 mm. The film substrate can be perforated or slit, and the flocked fibers can act as a transmitter and face the opposite direction to the first layer 205. Alternatively, the flocked fibers can face the first layer 205. In some embodiments, the second layer 210 may include felted polyurethane foam which has open cells and a thickness in the range of about 2 mm to about 5 mm. The felted polyurethane foam can have perforations through it in some modalities.
[0063] [0063] The second layer 210 generally has a first flat surface and a second flat surface opposite the first flat surface. The thickness of the second layer 210 between the first flat surface and the second flat surface can also vary according to the needs of a prescribed therapy. For example, the thickness of the second layer 210 can be decreased to relieve stress on other layers and to reduce the tension in the peripheral tissue. The thickness of the second layer 210 can also affect the formability of the second layer 210. In some embodiments, a thickness in the range of about 5 millimeters to 10 millimeters may be suitable.
[0064] [0064] In the example of Figure 2, dressing 104 may also include a fixing device, such as an adhesive
[0065] [0065] As illustrated in the example of Figure 2, in some embodiments, dressing 104 may include a release liner 245 to protect adhesive 240 prior to use. The release liner 245 can also provide stiffness to assist with, for example, implantation of dressing 104. The release liner 245 can be, for example, a wrapping paper, a film or polyethylene. In addition, in some embodiments, the release liner 245 may be a polyester material, such as polyethylene terephthalate (PET) or similar polar semicrystalline polymer. the use of a semicrystalline polar polymer for release liner 245 can substantially disable wrinkling or other deformation of the dressing 104. For example, the semicrystalline polar polymer can be highly oriented and resistant to softening, swelling or other deformation that may occur when placed in contact with components of dressing 104 or when subjected to environmental or temperature variations or sterilization. In addition, a release agent can be arranged on one side of the release liner 245 that is configured to contact the first layer 205.
[0066] [0066] Figure 2 also illustrates an example of a fluid conductor 250 and a dressing interface 255. As shown in the example of Figure 2, fluid conductor 250 can be a flexible tube that can be fluidly coupled in a end to dressing interface 255. Dressing interface 255 can be an elbow connector, as shown in the example in Figure 2, which can be placed over an opening 260 in cover 116 to provide a fluid path between the fluid conductor 250 and the fabric interface
[0067] [0067] One or more of the components of dressing 104 may be additionally treated with an antimicrobial agent in some embodiments. For example, second layer 210 may be foam, mesh or nonwoven coated with an antimicrobial agent. In some embodiments, the first layer may comprise antimicrobial elements, such as fibers coated with an antimicrobial agent. Additionally or alternatively, some embodiments of the first layer 205 may be polymer coated or mixed with an antimicrobial agent. In other examples, the fluid conductor 250 may, additionally or alternatively, be treated with one or more antimicrobial agents. Suitable antimicrobial agents can include, for example, metallic silver, PHMB, iodine and their complexes and mixtures, such as povidone iodine, copper metallic compounds, chlorhexidine or some combination of these materials.
[0068] [0068] Additionally or alternatively, one or more of the components may be coated with a mixture that may include citric acid and collagen, which can reduce biofilms and infections. For example, the second layer 210 may be a foam coated with such a mixture.
[0069] [0069] Individual components of dressing 104 can be bonded or otherwise attached to each other with a solvent or non-solvent adhesive, or with thermal welding, for example, without adversely affecting fluid management.
[0070] [0070] Figure 3 is a schematic view of an example of the first layer 205 that illustrates additional details that can be associated with some modalities. As illustrated in the example in Figure 3, fluid constraints 220 can each essentially consist of one or more linear fenestrations or perforations that are about 3 millimeters long. Figure 3 further illustrates an example of a uniform distribution pattern of fluid restrictions 220. In Figure 3, fluid restrictions 220 are substantially coextensive with the first layer 205 and are distributed across the first layer 205 in a grid of rows and parallel columns, in which fluid restrictions 220 are also mutually parallel to each other. In some embodiments, the rows can be spaced about 3 millimeters in the center, and fluid restrictions 220 in each row can be spaced about 3 millimeters in the center as shown in the example in Figure 3. Fluid restrictions 220 in adjacent rows can be aligned or offset. For example, adjacent rows can be moved, as shown in Figure 3, so that fluid restrictions 220 are aligned in alternating rows and separated by about 6 millimeters. The spacing of fluid restrictions 220 may vary in some embodiments to increase the density of fluid restrictions 220 according to therapeutic requirements.
[0071] [0071] Figure 4 is a side view of an example of the first layer 205 that illustrates additional details that can be associated with some modalities of fluid restrictions 220. As shown, fluid restrictions 220 can be fenestrated cut through the first layer 205, which can cause local deformation of the first layer 205 around fluid constraints 220. For example, fluid constraints 220 may have raised edges 405. The deformation shape factor may have an asymmetry in fluid constraints 220. At rest, as in the upper illustration of Figure 4, the raised edges 405 can be retracted on top of each other. A pressure gradient across fluid constraints 220 can separate the raised edges 405, as shown in the lower illustration in Figure 4. Asymmetry can allow fluid to move more easily in one direction than in another direction, and fluid constraints 220 can act as a check valve and, more particularly, as a duckbill valve. In this way, fluid restrictions 220 may restrict the transfer of liquid through the first layer 205 from the first side to the second side.
[0072] [0072] Figure 5 is a side view of another exemplary configuration of fluid restrictions 220 that illustrates additional details that can be associated with some embodiments of the first layer 205. In Figure 5, fluid restrictions 220 comprise perforations (or notches) ) which can be linear perforations formed by material removal. For example, each of the fluid restrictions 220 can be holes 500 that are about 3.0 mm long and about 0.8 mm wide.
[0073] [0073] Figure 6 is a side view of another exemplary configuration of fluid restrictions 220 that illustrates additional details that can be associated with some embodiments of the first layer 205. In Figure 6, fluid restrictions 220 include a combination of fenestrations that have 405 raised edges and perforations that have 500 holes.
[0074] [0074] In some embodiments, a central zone of the first layer 205 may include a greater proportion of perforations than of fenestrations. The central zone can cover about 50% of the area of the first layer 205, and the central zone can be coextensive with about 50% of a transmission area. The peripheral zone can be coextensive with about 50% of the transmission area. A ratio between perforations and fenestrations in the central zone of the first layer 205 can be greater than about 1: 1. For example, the central zone of the first layer 205 may have a ratio between perforations and fenestrations of about 8: 2. The peripheral zone, which can be about 50% of the available transmission area, can have a ratio between drilling and fenestration of about 2: 8. In other embodiments, the first layer 205 can include two or more zones, and a ratio between the perforations and fenestrations in a first zone can be about 8: 2, while a ratio between the perforations and fenestrations in a second zone it can be about 2: 8.
[0075] [0075] Perforations and fenestrations with different formats can be used in some modalities. For example, perforations can be circular, linear or oval. In some modalities, fenestrations can be formed from serrated or toothed saws. Toothed saw shapes may show less resistance to fluid flow due to the easier opening capacity, thus enabling a higher flow rate, or the ability to handle higher viscosity fluids.
[0076] [0076] The cover 116, the second layer 210 and the first layer 205, or various combinations, can be assembled before application or in situ. For example, cover 116 can be laminated to second layer 210, and first layer 205 can be laminated to second layer 210 opposite cover 116 in some embodiments. The first layer 205 can provide a smooth surface opposite to the second layer 210. In some embodiments, one or more layers of the fabric interface 114 can be coextensive. For example, the first layer 205 can be cut flush with the edge of the second layer 210, exposing the edge of the second layer 210, as shown in the embodiment of Figure 2. In other embodiments, the first layer 205 can overlap the edge of the second layer 210. In some embodiments, dressing 104 may be provided as a single composite dressing. For example, the first layer 205 can be coupled to the cover 116 in order to enclose the second layer 210, the first layer 205 being configured to face a tissue site.
[0077] [0077] In use, release liner 245 (if included) can be removed to expose the first layer 205, which can be placed inside, on, in or otherwise close to a fabric site, particularly at a site of superficial tissue and in the adjacent epidermis. The first layer 205 can be interposed between the second layer 210 and the tissue site and the adjacent epidermis, which can substantially reduce or eliminate adverse interaction with the second layer 210. For example, the first layer 205 can be placed on a superficial wound (including wound edges) and undamaged epidermis to prevent direct contact with the second layer 210. Treatment of a superficial wound or placing dressing 104 on a superficial wound includes placing dressing 104 immediately adjacent on the body surface or extending over at least a portion of the body surface. The treatment of a superficial wound does not include placing the dressing 104 entirely within the body or entirely under the surface of the body, such as placing a dressing within an abdominal cavity. The cover 116 can be sealed to a fixing surface, such as the peripheral epidermis to a tissue site, around the second layer 210 and the first layer 205.
[0078] [0078] The geometry and dimensions of the fabric interface 114, the cover 116 or both may vary in order to suit a specific application or anatomy. For example, the geometry or dimensions of the fabric interface 114 and the cover 116 can be adapted to provide an effective and reliable seal against difficult anatomical surfaces, such as an elbow or heel, in and around a fabric site. . Additionally or alternatively, the dimensions can be modified to increase the surface area of the first layer 205 to enhance the movement and proliferation of epithelial cells in a tissue site and reduce the likelihood of granulation tissue growth.
[0079] In this way, dressing 104 can provide a sealed therapeutic environment close to a tissue site, substantially isolated from the external environment, and the negative pressure source 102 can reduce pressure in the sealed therapeutic environment. Negative pressure in the sealed environment can compress the second layer 210 into the first layer 205, which can deform the surface of the first layer 205 to provide an irregular, coarse or jagged profile that can induce macrostretching and micro-stretching at the tissue site in some modalities. The negative pressure applied through the fabric interface 114 can also create a negative pressure differential through fluid restrictions 220 in the first layer 205, which can open fluid restrictions 220 to allow movement of exudate and other liquid through the fluid restrictions 220 for the second layer 210 and the container 106. For example, in some embodiments in which fluid restrictions 220 may comprise perforations through the first layer 205, a pressure gradient through the perforations may stretch the adjacent material of the first layer 205 and increase the dimensions of the perforations to allow the movement of the liquid through them, similar to the operation of a duckbill valve.
[0080] [0080] If the negative pressure source 102 is removed or turned off, the pressure differential through fluid restrictions 220 can dissipate, allowing fluid restrictions 220 to return to an unstretched or resting state and prevent or reduce the rate of return of the exudate or other liquid that moves to the tissue site through the first layer 205.
[0081] [0081] In some applications, a filler can also be arranged between a tissue site and the first layer 205. For example, if the tissue site is a superficial wound, a wound filler can be applied within the periphery, and the first layer 205 can be arranged over the periphery and the wound filler. In some embodiments, the filler can be a transmitter, such as open cell foam. The filler may comprise or consist essentially of the same material as that of the second layer 210 in some embodiments.
[0082] [0082] Additionally or alternatively, the fabric interface 114 can be formed into strips suitable for use as bridges or to fill tunnel wounds, for example. Strips having a width of about 5 mm to 30 mm may be suitable for some modalities.
[0083] [0083] In addition or alternatively, the first layer 205 may comprise reinforcement fibers to increase its tensile strength, which can be advantageous for use in tunnel wounds.
[0084] [0084] Additionally or alternatively, the instillation solution or other fluid can be delivered to dressing 104, which can increase pressure at tissue interface 114. Increasing pressure at tissue interface 114 can create a positive pressure differential through fluid restrictions 220 on first layer 205, which can open or expand fluid restrictions 220 from its resting state to allow the instillation solution or other fluid to be delivered to the tissue site.
[0085] [0085] Figure 7 is an assembly view of another example of dressing 104 of Figure 1 which illustrates additional details that can be associated with some embodiments in which the fabric interface 114 can comprise additional layers. In the example of Figure 7, the fabric interface 114 comprises a third layer 705 in addition to the second layer 210 and the first layer 205. In some embodiments, the third layer 705 may be adjacent to the first layer 205 opposite the second layer 210. The third layer 705 can also be attached to the first layer 205 in some embodiments.
[0086] [0086] The third layer 705 may comprise or consist essentially of a sealing layer formed from a soft malleable material suitable for providing a fluid seal with a fabric site and may have a substantially flat surface. For example, the third layer 705 may comprise, without limitation, a silicone gel, a soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrenic copolymer gel, a foamed gel, a soft cell foam closed, such as polyurethanes and polyolefins coated with an adhesive, polyurethane, polyolefin or copolymers of hydrogenated styrenics. In some embodiments, the third layer 705 may have a thickness between about 200 microns (one) and about 1,000 microns (pum). In some embodiments, the third layer 705 may have a hardness between about 5 Shore OO and about 80 Shore OO. In addition, the third layer 705 may be comprised of hydrophobic or hydrophilic materials. For example, the third layer 705 may include a hydrophobic gel.
[0087] [0087] In some embodiments, the third layer 705 may be a material coated with a hydrophobic product. For example, the third layer 705 may be formed by coating a spaced material, such as, for example, woven, non-woven, molded or extruded with a hydrophobic material. The hydrophobic material for the coating can be a soft silicone, for example.
[0088] [0088] The third layer 705 may have a periphery 710 surrounding or around an inner portion 715 and openings 720 arranged through the periphery 710 and the inner portion 715. The inner portion 230 may correspond to a surface area of the second layer 210 in some examples. The third layer 705 may also have corners 725 and edges 730. Corners 725 and edges 730 may form part of the periphery 710. The third layer 705 may have an inner margin 735 around the inner portion 715 disposed between the inner portion 715 and the periphery 710. The inner margin 735 can be substantially free of the openings 720, as shown in the example of Figure 3. In some examples, as shown in Figure 3, the inner portion 715 can be symmetrical and centrally arranged in the third layer 705.
[0089] [0089] The openings 720 can be formed by cutting or applying local RF or ultrasonic energy, for example, or by using other suitable techniques to form a hole. The openings 720 can have a uniform distribution pattern or can be randomly distributed in the third layer 705. The openings 720 in the third layer 705 can have many shapes, including circles, squares, stars,
[0090] [0090] Each of the openings 720 may have uniform or similar geometric properties. For example, in some embodiments, each of the openings 720 may be circular openings having substantially the same diameter. In some embodiments, the diameter of each of the openings 720 can be between about 1 millimeter and about 50 millimeters. In other embodiments, the diameter of each of the openings 720 can be between about 1 millimeter and about 20 millimeters.
[0091] [0091] In other embodiments, the geometric properties of the openings 720 may vary. For example, the diameter of the openings 720 can vary depending on the position of the openings 720 in the third layer 705, as shown in Figure 7. In some embodiments, the diameter of the openings 720 in the periphery 710 of the third layer 705 may be larger than the diameter of the openings. openings 720 in the inner portion 715 of the third layer 705. For example, in some embodiments, the openings 720 arranged at the periphery 710 may have a diameter between about 9.8 mm and about 10.2 mm. In some embodiments, the openings 720 arranged in the corners 725 can have a diameter between about 7.75 mm and about 8.75 mm. In some embodiments, the openings 720 arranged in the inner portion 715 may have a diameter between about 1.8 millimeters and about 2.2 millimeters.
[0092] [0092] At least one of the openings 720 at the periphery 710 of the third layer 705 can be positioned at the edges 730 of the periphery 710 and can have an open or exposed inner cut at the edges 730 which is in fluid communication in a lateral direction with the edges 730 The lateral direction can refer to a direction for the edges 730 and in the same plane as the third layer 705. As shown in the example in Figure 7, the openings 720 on the periphery 710 can be positioned close to the edges 730 or on them and be in fluid communication in a lateral direction with the edges 730. The openings 720 positioned close to the edges 730 or at them can be spaced substantially equidistant around the periphery 710. Alternatively, the spacing of the openings 720 close to the edges 730 or at the same edges it can be irregular.
[0093] [0093] As illustrated in the example of Figure 7, in some embodiments, the release liner 245 can be attached to the third layer 705 or positioned adjacent to it to protect the adhesive 240 before use. In some embodiments, the release liner 245 may have a surface texture that can be printed on an adjacent layer, such as the third layer 705. In addition, a release agent can be arranged on one side of the release liner 245 which is configured to contact the third layer 705.
[0094] [0094] Individual components of dressing 104 in the example of Figure 7 can be bonded or otherwise attached to each other with a solvent or non-solvent adhesive or with thermal welding, for example, without adversely affecting fluid management. In addition, the first layer 205 or the second layer 210 can be coupled to the margin 735 of the third layer 705 in any suitable manner, such as with a solder or an adhesive, for example.
[0095] [0095] The cover 116, the second layer 210, the first layer 205, the third layer 705 or various combinations can be assembled before application Or in situ. For example, cover 116 can be laminated to second layer 210, and first layer 205 can be laminated to second layer 210 opposite cover 116 in some embodiments. The third layer 705 can also be coupled to the first layer 205 opposite the second layer 210 in some embodiments. In some embodiments, one or more layers of the fabric interface 114 may be coextensive. For example, the first layer 205, the third layer 705 or both can be cut flush with the edge of the second layer 210, exposing the edge of the second layer 210, as illustrated in the embodiment of Figure 7. In other embodiments, the first layer 205 , the third layer 705 or both may overlap the edge of the second layer 210. In some embodiments, dressing 104 may be provided as a single composite dressing. For example, the third layer 705 can be coupled to the cover 116 in order to enclose the second layer 210 and the first layer 205, the third layer 705 being configured to face a tissue site. Additionally or alternatively, the first layer 205, the third layer 705 or both can be arranged on both sides of the second layer 210 and joined to enclose the second layer 210.
[0096] [0096] Figure 8 is a schematic view of an exemplary configuration of the openings 720 that illustrates additional details that can be associated with some modalities of the third layer 705. In some embodiments, the openings 720 shown in Figure 8 can be associated only with the portion interior 715. In the example of Figure 8, the openings 720 are generally circular and have a diameter of about 2 millimeters. Figure 8 also illustrates an example of a uniform distribution pattern of openings 720 in the inner portion 715. In Figure 8, the openings 720 are distributed across the inner portion 715 in a grid of parallel rows and columns. In each row and column, the openings 720 can be equidistant from each other, as illustrated in the example in Figure 8. Figure 8 illustrates an exemplary configuration that can be particularly suitable for many applications, where the openings 720 are separated into about 6 millimeters along each row and column, with an offset of 3 millimeters.
[0097] [0097] Figure 9 is a schematic view of the third exemplary layer 705 of Figure 8 superimposed on the first layer 205 of Figure 3 that illustrates additional details that can be associated with some exemplary embodiments of the fabric interface 114. For example, as illustrated in In Figure 9, fluid constraints 220 may be aligned, overlapped, leveled or otherwise fluidly coupled to openings 720 in some embodiments. In some embodiments, one or more of the fluid restrictions 220 can be flush with the openings 720 only in the inner portion 715 or only partially flush with the openings 720. The fluid restrictions 220 in the example in Figure 9 are generally configured so that each of the fluid restrictions 220 is flush with only one of the openings 720. In other examples, one or more of the fluid restrictions 220 can be flush with more than one of the openings 720. For example, any one or more of the restrictions fluid flow 220 may be a perforation or fenestration that extends through two or more of the openings 720. Additionally or alternatively, one or more of the fluid constraints 220 may not be flush with any of the openings 720.
[0098] [0098] As shown in the example in Figure 9, the openings 720 can be sized to expose a portion of the first layer 205, fluid restrictions 220 or both through the third layer 705. In some embodiments, one or more of the openings 720 can be sized to expose more than one of the fluid restrictions 220. For example, some or all of the openings 720 can be sized to expose two or three of the fluid restrictions 220. In some examples, the length of each of the fluid constraints 220 can be substantially equal to the diameter of each of the openings 720. More generally, the average dimensions of the fluid constraints 220 are substantially similar to the average dimensions of the openings
[0099] [0099] Figure 10 is a schematic view of another example of the third layer 705 that illustrates additional details that can be associated with some modalities. As shown in the example in Figure 10, the third layer 705 may have one or more fluid restrictions, such as valves 1000, instead of or in addition to the openings 720 in the inner portion 715. The valves 1000 can be elastomeric. In some embodiments in which the third layer 705 includes one or more of the valves 705, the first layer 205 can be omitted. For example, in some embodiments, the fabric interface 114 may consist essentially of the second layer 210 and the third layer 705 of Figure 10 with the valves 705 arranged in the inner portion 415.
[00100] [00100] Figure 11 and Figure 12 illustrate other exemplary configurations of valves 1000, in which valves 1000 generally each comprise a combination of intersecting slits or crossed slits. In some embodiments shown in Figure 11, valves 1000 generally have a “Y” shape. In some embodiments shown in Figure 12, valves 1000 generally have a cross shape or positive sign.
[00101] [00101] Figure 13 is an assembly view of another example of the fabric interface 114 of Figure 11. In the example in Figure 13, the first layer 205 is disposed adjacent to the two sides of the second layer 210. In some embodiments, for example, the first layer 205 can be laminated or otherwise mechanically connected to the two sides of the second layer 210. Additionally or alternatively, the third layer 705 may be disposed adjacent to one or more sides of the first layer 205 or it may be disposed adjacent to the second layer 210. In some embodiments, the third layer 705 may form a sleeve Or envelope around the first layer 205, the second layer 210 or both.
[00102] [00102] In use, release liner 245 (if included) can be removed to expose the third layer 705, which can be placed inside, on, in or otherwise close to a fabric site, particularly at a site of superficial tissue and adjacent epidermis. The third layer 705 and the first layer 205 can be interposed between the second layer 210 and the tissue site, which can substantially reduce or eliminate the ad versa interaction with the second layer
[00103] [00103] Removing release liner 245 can also expose adhesive 240, and cover 116 can be attached to a fixation surface, such as the epidermis on the periphery of a tissue site, around the second layer 210 and the first layer 205. For example, adhesive 240 may be in fluid communication with a fixing surface through openings 420 at least at the periphery 710 of the third layer
[00104] [00104] Once the dressing 104 is in the desired position, the adhesive 240 can be pressed through the openings 720 to connect the dressing 104 to the fixing surface. The openings 720 at the edges 730 may allow adhesive 240 to flow around the edges 730 to enhance the adhesion of the edges 730 to a fixing surface.
[00105] [00105] In some embodiments, the openings or holes in the third layer 705 can be sized to control the amount of adhesive 240 in fluid communication with the openings 720. For a certain geometry of the corners 725, the relative sizes of the openings 720 can be configured to maximize the surface area of adhesive 240 exposed and in fluid communication through the openings 720 in the corners 725. For example, as shown in Figure 3, the edges 730 can substantially intersect at a right angle, or about 90 degrees, to define corners 725. In some embodiments, corners 725 can have a radius of about 10 millimeters. Additionally, in some embodiments, three of the openings 720 that have a diameter between about 7.75 mm and about 8.75 mm can be positioned in a triangular configuration at the corners 725 to maximize the exposed surface area for adhesive 240. In other modalities, the size and number of openings 720 in corners 725 can be adjusted as needed, depending on the chosen geometry of corners 725, to maximize the exposed surface area of adhesive 240. Additionally, openings 720 in corners 725 can be completely accommodated in the third layer 705, substantially preventing fluid communication in a lateral direction outside the corners
[00106] [00106] In some embodiments, the adhesion resistance of adhesive 240 may vary in different places of the dressing
[00107] [00107] The geometry and dimensions of the fabric interface 114, the cover 116 or both may vary to suit a specific application or anatomy. For example, the geometry or dimensions of the fabric interface 114 and the cover 116 can be adapted to provide an effective and reliable seal against difficult anatomical surfaces, such as an elbow or heel, in and around a fabric site. . Additionally or alternatively, the dimensions can be modified to increase the surface area of the third layer 705 to enhance the movement and proliferation of epithelial cells in a tissue site and reduce the likelihood of granulation tissue growth.
[00108] [00108] Additionally, dressing 104 may allow reapplication or repositioning to reduce or eliminate leaks, which may be caused by creases and other discontinuities in dressing 104 or a tissue site. The ability to rectify leaks can increase the reliability of therapy and reduce power consumption in some modalities.
[00109] [00109] In this way, dressing 104 can provide a sealed therapeutic environment close to a tissue site, substantially isolated from the external environment, and the negative pressure source 102 can reduce pressure in the sealed therapeutic environment. The third layer 705 can provide an effective and reliable seal against difficult anatomical surfaces, such as an elbow or heel, in or around a tissue site. Additionally, dressing 104 may allow reapplication or repositioning to correct air leaks caused by creases or other discontinuities in dressing 104, for example. The ability to rectify leaks can increase the effectiveness of therapy and reduce power consumption in some modalities.
[00110] [00110] If not already configured, dressing interface 255 can be arranged over opening 260 and attached to cover 116. Fluid conductor 250 can be fluidly coupled to dressing interface 255 and negative pressure source 102 .
[00111] [00111] The negative pressure applied through the fabric interface 114 can create a negative pressure differential through fluid restrictions 220 in the first layer 205, which can open or expand fluid restrictions 220. For example, in some embodiments in whereas fluid restrictions 220 may comprise substantially closed fenestrations through the first layer 205, a pressure gradient through the fenestrations can stretch the adjacent material of the first layer 205 and increase the dimensions and / or deform the fenestrations to allow the liquid to move through similar to the operation of a duckbill valve. Opening fluid restrictions 220 may allow movement of exudate and other liquid through fluid restrictions 220 to second layer 210 and container 106. Changes in pressure can also cause second layer 210 to expand and contract, and the inner margin 735 can protect the epidermis from irritation. The first layer 205 and the third layer 705 can also substantially reduce or prevent exposure of the tissue to the second layer 210, which can inhibit tissue growth in the second layer 210. Deformation of the first layer 205 can occur to a greater extent in a central portion than in a peripheral zone, which can allow a greater volume of fluid to flow through fluid restrictions 220 or fenestrations 400.
[00112] [00112] In some embodiments, by mixing the occurrence of perforations 500 and fenestrations 400 in the first layer 205, the fluid flow can be more readily controlled to increase the flow of fluid in the central area of the dressing 104, while restricting the flow fluid return. The greater valvular functionality of the peripheral zone, which is more likely to cover a periphery or intact skin, can reduce fluid reflux and the risks of maceration. The tendency of greater flow and / or lower pressure drop over the central area of the dressing can encourage the fluid to be drawn in the opposite direction to the perimeter of the dressing. In some modalities, perforations and fenestrations can reduce the risk of the fluid reaching and / or persisting in an area of periphery or intact skin. Dressings can also be more efficient in delivering instillation fluid to the central portion of the dressing and the wound and restrict the flow of fluid to the periphery area. If the negative pressure source 102 is removed or turned off, the pressure differential across fluid restrictions 220 can dissipate, allowing fluid restrictions 220 to close and prevent exudate or other liquid from returning to the tissue site through the first layer 205.
[00113] [00113] In some applications, a filler can also be arranged between a tissue site and the third layer 705. For example, if the tissue site is a superficial wound, a wound filler can be applied inside the periphery, and the third layer 705 can be arranged over the periphery and the wound filler. In some embodiments, the filler can be a transmitter, such as open cell foam. The filler may comprise or consist essentially of the same material as that of the second layer 210 in some embodiments.
[00114] [00114] Additionally or alternatively, the instillation solution or other fluid can be delivered to dressing 104, which can increase pressure at tissue interface 114. Increasing pressure at tissue interface 114 can create a positive pressure differential through fluid restrictions 220 on first layer 205, which can open fluid restrictions 220 to allow the instillation solution or other fluid to be delivered to a tissue site.
[00115] [00115] Figure 14 is a schematic cross-sectional view of an example transmitter that can be associated with some modalities of the second layer 210. As illustrated in the example in Figure 14, the transmitter can be a fluid management assembly 1402 that can include a first drain layer 1404, a second drain layer 1406 and, optionally, an absorbent 1408. The absorbent 1408 can be positioned between the first drain layer 1404 and the second drain layer 1406. The first drain layer 1404 can have a grain structure (not shown) adapted to drain fluid along a surface of the first drain layer 1404. Similarly, the second drain layer 1406 may have a grain structure (not shown) adapted to drain fluid along of a surface of the second drainage layer 1406. For example, the first drainage layer 1404 and the second drainage layer 1406 may drain or otherwise transpose tar fluid in a lateral direction along the surfaces of the first drain layer 1404 and the second drain layer 1406, respectively. The fluid can be transported in this way with or without the application of reduced pressure. The surfaces of the first drain layer 1404 and the second drain layer 1406 can be normal with respect to the thickness of each of the first drain layer 1404 and the second drain layer
[00116] [00116] A peripheral portion 1410 of the first drainage layer 1404 may be coupled to a peripheral portion 1412 of the second drainage layer 1406 to define a drainage envelope 1414. In some exemplary embodiments, the drainage envelope 1414 may surround or, otherwise, wrap the absorbent 1408 between the first drain layer 1404 and the second drain layer 1406.
[00117] [00117] Fluid management assembly 1402 may include, without limitation, any suitable number of drainage layers as desired to treat a specific tissue site. Additionally or alternatively, some embodiments of absorbent 1408 may comprise or consist essentially of a plurality of absorbent layers 1416 between the first drain layer 1404 and the second drain layer 1406. Additionally, as shown in Figure 14, at least one layer of drainage intermediate drain 1420 can be disposed between absorbent layers 1416.
[00118] [00118] The sides 1418 of the absorbent layers 1416 can remain in fluid communication with each other to enhance efficiency. Similarly, in the embodiment of Figure 14, the sides 1422 of the intermediate drainage layer
[00119] [00119] In some embodiments, absorbent 1408 may comprise or consist of a hydrophilic material or other absorbent material. Suitable materials for absorbent 1408 may include material LuquafleeceO, Texsus FP2326, BASF 402c, Technical Absorbents 2317 available from Technical Absorbents (www. Techabsorbents.com), sodium polyacrylate superabsorbents, cellulosic (carboxymethylcellulose and salts, such as CMC of sodium) or alginates. Suitable materials for the first drainage layer 1404 and the second drainage layer 1406 can include any material that has a grain structure capable of draining fluids, such as Libeltex TDL2 80gsm.
[00120] [00120] The fluid management assembly 1402 can be a pre-laminated structure manufactured in a single location or simply individual layers of material stacked on top of each other. The individual layers of the fluid management assembly 1402 can be bonded or otherwise pressed together without adversely affecting fluid management, for example, with the use of a solvent or non-solvent adhesive or by thermal welding.
[00121] [00121] Figure 15 is a perspective view of an exemplary transmitter that can be associated with some modalities of the second layer 210. As illustrated in the example of Figure 15, the transmitter can be a polymeric mesh 1500 that can include an egg array interconnected 1502 which have a truncated ellipsoidal shape. The interconnected egg array may include corner eggs 1504, edge eggs 1506 and optionally, but preferably, at least one central egg 1508. The arrangement may contain about 50 rows and about 50 columns, but it should be understood that the The arrangement can be of any reasonable size and can comprise any number of rows and any number of columns sufficient to assist in the treatment of a tissue site.
[00122] [00122] In some embodiments, the interconnected eggs may be polymeric, as comprised of a polyolefin, a polyester, a polyamide, a polystyrene, a polydiolefin, a polyacrylonitrile, a polysiloxane or a copolymer or combination thereof. In certain embodiments, interconnected eggs may be non-adherent to a tissue site. In some embodiments, each of the interconnected eggs has a surface hardness of about 0 Shore A to about 25 Shore A. In some embodiments, the top surface, the bottom surface, or both, of the interconnected egg array, may exhibit a hardness from about O Shore A to about 25 Shore A. In some embodiments not shown in the Figures, the top surface, the bottom surface, or both, of the interconnected egg array, may include a coating arranged on them that exhibits a hardness of at least 55 Shore A. In embodiments, when a coating is present, the coating may be comprised of a cellulosic material, a polyester, a polyamide, a polycarbonate, a peralogenated polyolefin, an aramid, a polybenzimidazole, a polysulfone or a copolymer, a combination or crosslinked gel thereof.
[00123] [00123] In some embodiments, at least a portion of the interconnected eggs may include one or more grooves on an outer surface of each egg that extend at least partially in a direction from its longest main geometric axis. In embodiments in which one or more grooves are present, each groove can have an average depth of at most 30% of a diameter of each interconnected egg along a direction of the main geometry axis different from that of the longest main geometry axis. Additionally or alternatively, at least a portion of the interconnected eggs may have an external texture, either in relief or in counter-relief, which may be systematic or random, such as texture patterns commercially available from Standex Int'l. Ltd. from London, England.
[00124] [00124] It may be desirable, in some modalities, that the portions of the ellipsoidal surfaces of the interconnected eggs that form the upper surface of the arrangement, the lower surface of the arrangement, or both protrude above / below the portions that define the fluid paths through the arrangement. Without sticking to the theory, it is believed that one or more of the sizes, shapes and component materials that make up the interconnected eggs and define the fluid paths between them can be adapted to allow negative pressure to be communicated through the arrangement, such as through fluid paths without complete collapse under the applied negative pressure.
[00125] [00125] The second layer 1500 can be produced using any viable technique, such as compression or injection molding using one or more pre-produced shapes. If more than one pre-produced form is used, the forms can be combined later, such as by fusion joining or an equivalent technique, to form a synthesized wound filler. However, continuous or semi-continuous fabrication can be employed as an alternative to molding, for example, with the use of a rotating mold that can vary its orifice accordingly to allow the extrusion of the complex surfaces of the wound filler materials.
[00126] [00126] In some embodiments, the second layer 1500 can optionally comprise one or more additional materials. Such optional components can include, for example, active materials, such as preservatives, stabilizing agents, plasticizers, matrix strengthening materials, dyes and combinations thereof. Such optional components may include, additionally or alternatively, passive materials, for example, in situations where ex vivo detection may be important, such as a sufficient amount of magnetic, metallic or ceramic material to allow prompt ex vivo detection, such as by means of an MRI or X-ray apparatus. In addition or alternatively, the second layer 1500 may comprise one or more additional active materials, for example, antimicrobial agents that can be effective in assisting tissue healing. Non-limiting examples of such active materials may include non-steroidal anti-inflammatory drugs, such as acetaminophen, steroids, antimicrobial agents, such as penicillins or streptomycins, antiseptics, such as chlorhexidine, growth factors, such as fibroblast growth factor or platelet-derived growth factor and other well-known therapeutic agents, alone or in combination. If present, such active materials can typically be included at any effective level that shows therapeutic efficacy, although, preferably, they are not at such a high level that it significantly contradicts any critical or desired physical, chemical or biological property of the wound filler. Depending on the therapeutic objective (or therapeutic objectives), the active material (or active materials) can be loaded at a level from about pppm to about 10% by weight of the layer (or layers) in which it is present, for example, from about 50 pppm to about 5 wt% or about 100 pppm to about 1 wt%.
[00127] [00127] In various embodiments, the second layer 210 may comprise or consist essentially of the transmitter 1500. Additionally or alternatively, the transmitter 1500 may be combined with other transmitting structures, other functional layers, or both, in the second layer 210.
[00128] [00128] Figure 16 is a partial view of another example of a transmitter that can be associated with some modalities of the second layer 210. For example, Figure 16 illustrates a transmitter that has protrusions 1604 that extend from a substrate 1606. As illustrated in the example in Figure 16, the shape of the protrusions 1604 can be substantially cylindrical. Alternatively, the cross-sectional shape of the protrusions 1604 can be square, rectangular, triangular, polygonal, elliptical or any other suitable shape. The protrusions 1604 can be tapered or have a uniform cross-sectional area along them.
[00129] [00129] The height, H, of protrusions 1604 is preferably between about 0.1 and 5.0 mm and, more preferably, about 2 mm. The width, W, of each protuberance is between about 0.1 and 2.0 millimeters and, more preferably, is about 0.25 to 0.5 millimeters. The width of the protrusions 1604 can be equal to the diameter, since the cross-sectional shape of each protrusion 1604 is circular. If protrusions 1604 are square in cross-sectional shape, the width of protrusions 1604 is an edge length of the square. For other cross-sectional formats, the width is the average of the longest lateral distance through the centroid of the cross section and the shortest lateral distance through the centroid of the cross section. The lateral spacing from center to center between each protrusion 1604 is preferably between about 0.1 and 1.0 millimeter and, more preferably, about 0.5 millimeter. The spacing of the protrusions 1604 creates distribution channels 1610 through which the reduced pressure can be delivered to the tissue site 31 and the exudates extracted from the tissue site. It is generally preferred that the height of the protrusions 1604 is greater than the width of the protrusions
[00130] [00130] the shape, dimensioning and spacing of the protrusions 1604 can vary depending on the specific tissue site to be treated, the type of material from which the protrusions 1604 and the support substrate 1606 are produced and the amount of pressure reduced applied to the tissue site. For example, for tissue sites that are highly exudative, it may be advantageous to position the protrusions further apart to maintain suitable distribution channels 1610 between the protrusions 1604. In an embodiment of the present invention, the shape, dimensioning and spacing of the protrusions 1604 they are uniform for a specific second layer 1600. In other embodiments, the shape, dimensioning and spacing of protrusions 1604 may vary. For example, protrusions 1604 having different cross-sectional shapes can be arranged on the support substrate 41. Similarly, the sizing and spacing of protrusions 1604 can vary to provide more or less reduced pressure to selected portions of the tissue site. .
[00131] [00131] The presence and dimensioning of protrusions 1604 may allow protrusions 1604 to distribute reduced pressure to the tissue site, but may substantially reduce or prevent new tissue growing at the tissue site from attaching to protrusions 1604 of the second layer 1600. By eliminating the pores or cells that are typically used to deliver reduced pressure to a tissue site, new tissue may not be able to wrap around the walls that form the pores or cells. Although new tissue may develop in the field of 1604 protrusions and may still involve some of the 1604 protrusions,
[00132] [00132] In various embodiments, the second layer 210 may comprise or consist essentially of a transmitter having protrusions 1604. In addition or alternatively, protrusions 1604 may be combined with other transmitting structures, other functional layers, or both, in the second layer 210 .
[00133] [00133] The systems, devices and methods described in this document can provide significant advantages. For example, dressing 104 is simple to apply, without customization or special skills, which can reduce the time to apply and remove dressing 104. In some embodiments, dressing 104 may be a fully integrated negative pressure therapy dressing that can be applied to a tissue site (including the periphery) in one step, without being cut to size while still providing or improving many benefits of other negative pressure therapy dressings that require scaling. Such benefits may include good transmission, beneficial granulation, protection of the peripheral tissue against maceration, protection of the tissue site against spillage of materials and a connection with little trauma and high sealing. In addition, by transmitting pressure through the layers, the wound can be granulated, while reducing the opportunity for granulation tissue growth in the transmitter. These characteristics can be particularly advantageous for superficial wounds that have moderate depth and medium to high exudate levels. In some embodiments, dressing 104 can provide macro-staining to the edges of a tissue site and can substantially reduce or prevent peripheral tissue maceration. In addition, dressing 104 can conform to or be within a significant wound space.
[00134] [00134] Some modalities of dressing 104 may remain in the tissue site for at least 5 days, and some modalities may remain for at least 7 days. Antimicrobial agents in dressing 104 can extend the usable life of dressing 104 by reducing or eliminating risks of infection that can be associated with prolonged use, particularly, use with infected or highly exudative wounds.
[00135] [00135] The felted foam can allow a reduced profile of the dressing 104 in some embodiments, which can improve the formability. The use of a biopolymer, such as ORC collagen, can further confer the benefits of the biopolymer. Some modalities may allow the fluid to be absorbed in a tissue site, and some modalities may have a larger area behind the layers of film to allow greater movement of the valve. In addition, some modalities may provide a means to reduce biofilm and the accumulation of bacteria in the dressing structure.
[00136] [00136] Although shown in some illustrative modalities, an individual of ordinary skill in the art will recognize that the systems, apparatus and methods described in this document are susceptible to various changes and modifications that are within the scope of the attached claims. Furthermore, descriptions of various alternatives using terms, such as "or", do not require mutual exclusivity, unless clearly required by the context, and the indefinite articles "one" or "one" do not limit the matter to a single case , unless clearly required by the context.
[00137] [00137] Resources, elements and aspects described in the context of some modalities can also be omitted, combined or replaced by alternative resources that serve the same, equivalent or similar purposes, without departing from the scope of the invention defined by the attached claims. For example, one or more of the features of some layers can be combined with features of other layers to provide an equivalent function. Alternatively or additionally, one or more of the fluid restrictions 220 may have shapes similar to the formats described as exemplary for the 705 valves. In other examples, the first layer 205, the third layer 705 or some combination of the first layer 205 and the third layer 705 can be coupled to both sides of second layer 210.
[00138] [00138] Components can also be combined or eliminated in various configurations for purposes of sale, manufacture, assembly or USE. For example, in some configurations, dressing 104, container 106 or both can be separated from other components for manufacture or sale. In other exemplary configurations, dressing components 104 can also be manufactured, configured, assembled or sold independently or as a kit.
The attached claims present innovative and inventive aspects of the material described above, but the claims can also cover additional material not specifically mentioned in detail. For example, certain features, elements or aspects can be omitted from the claims if it is not necessary to distinguish innovative and inventive features from what is already known to an individual of ordinary skill in the art.
Resources, elements and aspects described in the context of some modalities can also be omitted, combined or replaced by alternative resources that serve the same, equivalent or similar purposes, without departing from the scope of the invention defined by the attached claims.

权利要求:
Claims (69)
[1]
1. I THINK TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE, characterized by comprising: a first layer that has a first side, a second side and fenestrations that have a raised edge extending from the first side, with the raised edge it is configured to expand in response to a pressure gradient through the first layer; a second layer adjacent to the first side, the second layer comprising a transmitter; and a cover attached to the second layer opposite the first layer, the cover comprising a polymer cloth.
[2]
2. DRESSING according to claim 1, characterized in that the first layer is hydrophobic.
[3]
DRESSING according to claim 1, characterized in that: the first layer is hydrophobic; the transmitter is hydrophobic; and the first layer is more hydrophobic than the transmitter.
[4]
4. DRESSING, according to claim 1, characterized in that the first layer comprises a polymeric film that has a contact angle with water greater than 90 degrees.
[5]
5. THINK, according to claim 1, characterized in that fenestrations are configured to restrict the transfer of liquid through the first layer from the first side to the second side.
[6]
6. DRESSING according to claim 1, characterized in that the first layer is configured to be interposed between the transmitter and the tissue site and at least partially exposed to the tissue site.
[7]
7. THINK, according to claim 1, characterized by the fenestrations being coextensive with the first layer.
[8]
8. THINK, according to claim 1, characterized by the fenestrations being coextensive with the transmitter.
[9]
9. THINK, according to claim 1, characterized by fenestrations being distributed through the first layer in a uniform pattern.
[10]
10. THINK, according to claim 1, characterized by fenestrations being distributed through the first layer in a grid of parallel rows and columns.
[11]
11. THINK, according to claim 1, characterized by: fenestrations are distributed through the first layer in parallel rows and columns; the parallel rows are spaced about 3 millimeters in the center; and the fenestrations in each of the parallel rows are spaced about 3 millimeters in the center.
[12]
12. DRESSING according to claim 1, characterized in that the first layer has a substantially flat surface.
[13]
13. I THINK, according to claim 1, characterized by fenestrations being asymmetric.
[14]
14. DRESSING according to claim 1, characterized in that the first layer is welded to the second layer.
[15]
DRESSING according to claim 1, characterized in that: the first layer is hydrophobic; and the first layer is soldered to the transmitter.
[16]
16. DRESSING according to claim 1, characterized in that the first layer comprises or consists of a polyethylene film or an ethyl methyl acrylate film.
[17]
17. DRESSING according to claim 1, characterized in that the first layer comprises or consists essentially of a polyethylene film having an area density of less than 30 grams per square meter.
[18]
18. PENSION according to claim 1, characterized in that: the first layer comprises or essentially consists of a polyethylene film or an ethyl methyl acrylate film; and the first layer is soldered to the transmitter.
[19]
19. DRESSING according to claim 1, characterized in that: the first layer comprises or consists essentially of a polyethylene film or an ethyl methyl acrylate film; the transmitter comprises polyurethane foam; and the first layer is soldered to the transmitter.
[20]
20. DRESSING, according to claim 1, characterized by:
the first layer comprises or consists essentially of a polyethylene film; the transmitter comprises polyurethane foam; and the polyethylene film is welded to the transmitter with polar interfaces.
[21]
21. PENSION according to claim 1, characterized in that: the first layer comprises or consists essentially of a polyethylene film laminated to an ethyl methyl acrylate film; the transmitter comprises polyurethane foam; and the ethyl methyl acrylate film is welded to the transmitter.
[22]
22. PENSION according to claim 1, characterized in that: the first layer comprises or consists essentially of a polyethylene film laminated to at least one of a polyamide film, copolyesters, ionomers and acrylics; and the first layer is soldered to the transmitter.
[23]
23. DRESSING according to claim 1, characterized in that it also comprises a display layer between the first layer and the second layer.
[24]
24. DRESSING according to claim 1, characterized in that the first layer comprises a silicone coating.
[25]
25. DRESSING according to claim 1, characterized in that the first layer comprises a fluorocarbon coating.
[26]
26. DRESSING according to claim 1, characterized in that it further comprises a fourth layer coupled to the first layer opposite the second layer, the fourth layer comprising a hydrophobic gel that has a plurality of openings.
[27]
27. PENSO, according to claim 1, characterized in that it also comprises a fourth layer coupled to the first layer opposite the second layer, the fourth layer comprising a hydrophobic gel that has flush openings with at least some of the fenestrations in the first layer.
[28]
28. DRESSING, according to claim 1, characterized in that it also comprises a fourth layer coupled to the first layer opposite the second layer, the fourth layer comprising a hydrophobic gel that has a plurality of openings configured to expose at least one portion of one of the fenestrations.
[29]
29. DRESSING, according to claim 1, characterized in that it also comprises a fourth layer coupled to the first layer opposite the second layer, the fourth layer comprising a hydrophobic gel that has a plurality of openings, the openings limiting an effective size of fenestrations.
[30]
30. I THINK TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE, characterized by comprising: a first layer comprising a film that has perforations and fenestrations through the film that are configured to expand in response to a pressure gradient across the film;
a second layer adjacent to the first layer, the second layer comprising a transmitter; and a cover adjacent to the second layer opposite the first layer.
[31]
31. PENSO according to claim 30, characterized in that: the film has a central zone and a peripheral zone; the transmitter is at least partially arranged adjacent to the central zone; the perforations are arranged in the central zone; and fenestrations are arranged in the peripheral zone.
[32]
32. DRESSING, according to claim 30, characterized in that: the film has a central zone; at least some of the perforations and fenestrations are arranged in the central zone; and a ratio between the perforations and fenestrations in the central zone is greater than 1: 1.
[33]
33. PENSO, according to claim 30, characterized in that: the film has a central zone; at least some of the perforations and fenestrations are arranged in the central zone; and the ratio between the perforations and fenestrations in the central zone is about 8: 2.
[34]
34. PENSO according to claim 30, characterized in that: the film has a peripheral zone; at least some of the perforations and fenestrations are arranged in the peripheral zone; and a ratio between perforations and fenestrations in the peripheral zone is less than 1: 1.
[35]
35. DRESSING according to claim 30, characterized in that: the film has a peripheral zone; at least some of the perforations and fenestrations are arranged in the peripheral zone; and a ratio between perforations and fenestrations in the peripheral zone is at most 2: 8.
[36]
36. DRESSING, according to claim 30, characterized in that: the film has a first zone and a second zone; a ratio between perforations and fenestrations in the first zone is greater than 1: 1; and a ratio between perforations and fenestrations in the second zone is less than 1: 1.
[37]
37. DRESSING, according to claim 30, characterized in that: the film has a first zone and a second zone; a ratio between the perforations and fenestrations in the first zone is about 8: 2; and the ratio between the perforations and fenestrations in the second zone is about 2: 8.
[38]
38. PENSO, according to claim 30, characterized in that: the film has a transmission area comprising a central zone and a peripheral zone; the central zone is coextensive with about 50% of the transmission area;
the peripheral zone is coextensive with about 50% of the transmission area; a ratio between perforations and fenestrations in the central zone is greater than 1: 1; and a ratio between perforations and fenestrations in the peripheral zone is less than 1: 1.
[39]
39. PENSO, according to claim 30, characterized in that: the film has a transmission area comprising a central zone and a peripheral zone; the central zone is coextensive with about 50% of the transmission area; the peripheral zone is coextensive with about 50% of the transmission area; a ratio between the perforations and fenestrations in the central zone is about 8: 2; and the ratio between perforations and fenestrations in the peripheral zone is about 2: 8.
[40]
40. PENSO, according to claim 30, characterized in that: the film has a transmission area comprising a central zone and a peripheral zone; the central zone is coextensive with about 50% of the transmission area; the peripheral zone is coextensive with about 50% of the transmission area; the transmitter is at least partially arranged adjacent to the central zone; a ratio between the perforations and fenestrations in the central zone is about 8: 2; and the ratio between perforations and fenestrations in the peripheral zone is about 2: 8.
[41]
41. I THINK TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE, characterized by comprising: a fluid control layer that comprises fluid restrictions that are elastomeric and configured to be responsive to a pressure gradient through the fluid control layer; a transmitting layer adjacent to the fluid control layer; a cover adjacent to the transmitting layer opposite the fluid control layer; and a sealing layer adjacent to the fluid control layer opposite the transmitting layer, the sealing layer comprising openings aligned with fluid restrictions; the fluid control layer and the sealing layer each having a contact angle with water of at least 70 degrees; the fluid control layer and the sealing layer each being less than 100 microns thick; and the fluid control layer and the sealing layer have a hardness in the range of 20 Shore A to 90 Shore A.
[42]
42. PENSION according to claim 41, characterized in that the fluid control layer comprises a polymeric film of polylactic acid, carboxymethyl cellulose or polycaprolactone.
[43]
43. PENSO, according to claim 41, characterized in that the fluid control layer comprises a film of xanthan gum mixed with at least one of collagen, oxidized regenerated cellulose and alginate.
[44]
44. PENSO, according to claim 41, characterized in that the fluid control layer comprises a film of xanthan gum and citric acid mixed with at least one of collagen, oxidized regenerated cellulose and alginate.
[45]
45. DRESSING according to claim 41, characterized in that the fluid control layer comprises a copolymerized film with dialkylcarbamoyl chloride.
[46]
46. DRESSING according to claim 41, characterized in that the fluid control layer comprises a film coated with petroleum jelly.
[47]
47. DRESSING according to claim 41, characterized in that the fluid control layer comprises a film coated with petroleum jelly which has a viscosity of at least 10,000 millipascals seconds.
[48]
48. DRESSING according to claim 41, characterized in that the fluid control layer comprises a film coated with a petroleum jelly that has a viscosity of at least 10,000 millipascal seconds and antimicrobial compounds.
[49]
49. PENSO, according to claim 41, characterized in that the fluid control layer comprises a film coated with petroleum jelly, the film being formed from at least one among polyethylene, polyurethane and ethyl methyl acrylate.
[50]
50. DRESSING, according to claim 41, characterized in that the fluid control layer comprises a film coated with a petroleum jelly which has a viscosity of at least 10,000 millipascal seconds and antimicrobial compounds, the film being formed from at least least one among polyethylene, polyurethane and ethyl methyl acrylate.
[51]
51. DRESSING according to claim 41, characterized in that the transmitting layer comprises felted polyurethane foam that has open cells.
[52]
52. DRESSING according to claim 41, characterized in that the transmitting layer comprises felted polyurethane foam that has open cells and a thickness in the range of 2 millimeters to 5 millimeters.
[53]
53. DRESSING according to claim 41, characterized in that the transmitting layer comprises: foam having open cells formed from felted polyurethane; and perforations through the foam.
[54]
54. DRESSING according to claim 41, characterized in that the transmitting layer comprises a 3D textile.
[55]
55. DRESSING according to claim 41, characterized in that the transmitting layer comprises at least two layers of textile fabric woven with intertwined polymeric threads.
[56]
56. DRESSING according to claim 41, characterized in that the transmitting layer comprises a drainage layer.
[57]
57. DRESSING according to claim 41, characterized in that the transmitting layer comprises an absorbent.
[58]
58. DRESSING according to claim 41, characterized in that the transmitting layer comprises: a first drainage layer; a second drainage layer; and an absorbent disposed between the first drainage layer and the second drainage layer.
[59]
59. DRESSING according to claim 41, characterized in that the transmitting layer comprises at least two sheets formed from sodium carboxymethylcellulose.
[60]
60. DRESSING according to claim 41, characterized in that the transmitting layer comprises a polymeric mesh.
[61]
61. DRESSING according to claim 41, characterized in that the transmitting layer comprises a polymeric mesh that has an open area of at least 70%.
[62]
62. DRESSING according to claim 41, characterized in that the transmitting layer comprises polymeric microspheres, and at least some of the fluid restrictions are fluidly coupled to the spaces between the polymeric microspheres.
[63]
63. I THINK according to claim 41, characterized in that the transmitting layer comprises polymeric projections, and at least some of the fluid restrictions are fluidly coupled to the spaces between the polymeric projections.
[64]
64. DRESSING according to claim 41, characterized in that the transmitting layer comprises an embossed polymeric film.
[65]
65. DRESSING according to claim 41, characterized in that the transmitting layer comprises cellulose.
[66]
66. DRESSING according to claim 41, characterized in that the transmitting layer comprises a layer of non-woven material.
[67]
67. DRESSING according to claim 41, characterized in that the transmitting layer comprises foam which has closed cells and perforations through the foam.
[68]
68. DRESSING according to claim 41, characterized in that the transmitting layer comprises: a film substrate; a plurality of fibers extending from the film substrate; and perforations or fenestrations in the film substrate.
[69]
69. SYSTEMS, APPLIANCES AND METHODS, characterized by being substantially as described in this document.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112019025031A2|2020-08-18|I think to treat a negative pressure tissue site and systems, devices and methods

---

KR20200016932A|2020-02-17|Dressing material which we can remove and attach for sound pressure therapy

---

JP2020523078A|2020-08-06|Composite dressing for promoting granulation and reducing maceration by negative pressure treatment

---

KR20200016929A|2020-02-17|Composite dressing for improving childcare and reducing smoke by using negative pressure treatment

---

US20190231600A1|2019-08-01|Systems, Apparatuses, And Methods For Negative-Pressure Treatment With Reduced Tissue In-Growth

---

US20200170842A1|2020-06-04|Multi-Layer Compartment Dressing And Negative-Pressure Treatment Method

---

KR20200016931A|2020-02-17|Dressing material that can be detached and attached for sticky exudates and drip infusions

---

KR20200016936A|2020-02-17|Customized composite dressing material for improving childcare and reducing smoke by using negative pressure treatment

---

CN110868969B|2022-01-11|Composite dressing for improving granulation growth and reducing maceration by negative pressure therapy

---

US11266537B2|2022-03-08|Dressing exhibiting low tissue ingrowth and negative-pressure treatment method

---

US20200375805A1|2020-12-03|Manifolding Apparatus Or Dressing Exhibiting Low Tissue Ingrowth And Negative-Pressure Treatment Method

---

US20200000643A1|2020-01-02|Long-Duration, Deep Wound Filler With Means To Prevent Granulation In-Growth

---

US20180353338A1|2018-12-13|Customizable Composite Dressings For Improved Granulation And Reduced Maceration With Negative-Pressure Treatment

---

CA3065517A1|2018-12-13|Composite dressings for improved granulation and reduced maceration with negative-pressure treatment

---

CN114007663A|2022-02-01|Composite dressing for tissue closure with negative pressure

---

CN114173728A|2022-03-11|Customizable dressing for large area negative pressure therapy

---

JP2021509608A|2021-04-01|Thick exudate and dressing to be peeled off and applied for dripping

---

CN113710210A|2021-11-26|Transparent peeling and placing dressing for negative pressure treatment

---

CN114144209A|2022-03-04|Systems, devices, and methods for negative pressure therapy with reduced tissue ingrowth and extended wear time

同族专利:

---

公开号 | 公开日

---

KR20200016934A|2020-02-17|

---

SG11201909386SA|2019-11-28|

---

WO2018226624A1|2018-12-13|

---

CA3060588A1|2018-12-13|

---

US20180353339A1|2018-12-13|

---

AU2018282156A1|2019-11-07|

---

RU2019142454A|2021-07-12|

---

CN110709038A|2020-01-17|

---

JP2020523082A|2020-08-06|

---

EP3634335A1|2020-04-15|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB0011202D0|2000-05-09|2000-06-28|Kci Licensing Inc|Abdominal wound dressing|

---

US7700819B2|2001-02-16|2010-04-20|Kci Licensing, Inc.|Biocompatible wound dressing|

---

US7227050B2|2002-12-31|2007-06-05|Ossur Hf|Method for producing a wound dressing|

---

EP2345437B1|2008-03-05|2014-04-23|KCI Licensing, Inc.|Dressing for applying reduced pressure to and collecting and storing fluid from a tissue site|

---

US9414968B2|2008-09-05|2016-08-16|Smith & Nephew, Inc.|Three-dimensional porous film contact layer with improved wound healing|

---

US8791315B2|2010-02-26|2014-07-29|Smith & Nephew, Inc.|Systems and methods for using negative pressure wound therapy to manage open abdominal wounds|

---

US8613733B2|2010-12-15|2013-12-24|Kci Licensing, Inc.|Foam dressing with integral porous film|

---

CA2889440A1|2012-10-25|2014-05-01|Kci Licensing, Inc.|Wound connection pad with pneumatic connection confirmation ability|

---

EP3797744A1|2014-05-09|2021-03-31|3M Innovative Properties Company|Dressing with contracting layer for linear tissue sites|

---

CA2952284A1|2014-06-18|2015-12-23|Smith & Nephew Plc|Wound dressing|GB201020236D0|2010-11-30|2011-01-12|Convatec Technologies Inc|A composition for detecting biofilms on viable tissues|

---

ES2748519T3|2010-12-08|2020-03-17|Convatec Technologies Inc|Wound exudate system accessory|

---

EP2648793B1|2010-12-08|2020-03-11|ConvaTec Technologies Inc.|Integrated system for assessing wound exudates|

---

WO2013066426A2|2011-06-24|2013-05-10|Kci Licensing, Inc.|Reduced-pressure dressings employing tissue-fixation elements|

---

GB2497406A|2011-11-29|2013-06-12|Webtec Converting Llc|Dressing with a perforated binder layer|

---

WO2018009873A1|2016-07-08|2018-01-11|Convatec Technologies Inc.|Fluid collection apparatus|

---

US20200375805A1|2017-10-26|2020-12-03|Kci Licensing, Inc.|Manifolding Apparatus Or Dressing Exhibiting Low Tissue Ingrowth And Negative-Pressure Treatment Method|

---

EP3866741A1|2018-10-17|2021-08-25|KCI Licensing, Inc.|Systems, apparatuses, and methods for negative-pressure treatment with reduce tissue in-growth|

---

WO2020159823A1|2019-01-29|2020-08-06|Kci Licensing, Inc.|Removable and replaceable dressing interface for a negative-pressure therapy system|

---

TWM578166U|2019-02-01|2019-05-21|嬌朋生技股份有限公司|Negative pressure wound dressing|

---

WO2020217179A1|2019-04-22|2020-10-29|Kci Licensing, Inc.|Transparent peel and place dressing for negative-pressure therapy|

---

WO2020256843A1|2019-06-20|2020-12-24|Kci Licensing, Inc.|Peel and place dressing for negative-pressure therapy|

---

CN114126557A|2019-06-26|2022-03-01|凯希特许有限公司|Dressing employing features for preventing maceration|

---

WO2020263481A1|2019-06-28|2020-12-30|Kci Licensing, Inc.|Dressings with polymer delivery|

---

WO2021019486A1|2019-08-01|2021-02-04|Kci Licensing, Inc.|Hand dressing for use with negative pressure wound therapy|

---

WO2021044308A1|2019-09-05|2021-03-11|Kci Licensing, Inc.|Long-term wear tissue interfaces for high-closure force negative- pressure therapy dressings|

---

WO2021090276A1|2019-11-07|2021-05-14|Kci Licensing, Inc.|Means to reduce pressure reduction experienced with a collagen foam interface layer|

---

WO2021094946A1|2019-11-11|2021-05-20|Kci Licensing, Inc.|Wound sealing film|

---

WO2021116977A1|2019-12-13|2021-06-17|Kci Licensing, Inc.|Conformable dressing for negative-pressure treatment of large areas|

---

CN113712735A|2021-11-03|2021-11-30|上海大博医疗科技有限公司|Portable wound surface management dressing|

法律状态:
2021-07-13| B25A| Requested transfer of rights approved|Owner name: 3M INNOVATIVE PROPERTIES COMPANY (US) |

---

2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201762516540P| true| 2017-06-07|2017-06-07|

---

US201762516550P| true| 2017-06-07|2017-06-07|

---

US201762516566P| true| 2017-06-07|2017-06-07|

---

US62/516,566|2017-06-07|

---

US62/516,550|2017-06-07|

---

US62/516,540|2017-06-07|

---

US201762565754P| true| 2017-09-29|2017-09-29|

---

US62/565,754|2017-09-29|

---

PCT/US2018/035957|WO2018226624A1|2017-06-07|2018-06-05|Composite dressings for improved granulation and reduced maceration with negative-pressure treatment|

---